Avoid use of ondansetron in patients with congenital long QT syndrome, and monitor those with electrolyte abnormalities, CHF, bradyarrhythmias, or those taking concomitant medications that prolong the QT interval.
August 2011 Safety Labeling Changes with revisions to Prescribing Information
Potential for reduced battery performance can lead to the sudden loss of therapy and the return of underlying symptoms and/or therapy withdrawal symptoms.
Disponibili on line nuove e importanti informazioni di sicurezza
riguardanti il medicinale NPLATE e aggiornamento del Riassunto delle
Caratteristiche del Prodotto (RCP)
Patients treated with TNFα blockers are at increased risk for developing serious infections.
Disponibili on line nuove e importanti informazioni sul medicinale Multaq.
Aggiornamento sulla fornitura di CAELYX® (doxorubicina
liposomiale peghilata) 2 mg/ml concentrato per soluzione per infusione in
flaconcino da 10 ml e 25 ml e
importanti raccomandazioni sul trattamento dei pazienti.
Reports of hypersensitivity reactions, including anaphylaxis (a life-threatening allergic reaction), angioedema, low blood pressure, rapid heart rate, swollen tongue, difficulty breathing, wheezing, or rash.
Reclast should not be used in patients with creatinine clearance less than 35 mL/min or in patients with evidence of acute renal impairment.
High risk of infection from antiseptic surgical preparations that have been prepared, packaged, or held under insanitary conditions.
80.211.154.110
